Biotechnology is one of those sectors that is totally out of grace after it came down sharply in the second half of 2015, as market volatility rose sharply. The first chart shows that the biotech index (represented by the IBB ETF) lost
April 4, 2016
Aeglea Biotherapeutics Inc. (AGLE) expects to raise $51.4 million in its upcoming IPO. Based in Austin, Texas, Aeglea Biotherapeutics is a biotechnology company developing enzyme-based therapeutics to treat disorders of metabolism and cancer. AGLE will offer 3.5 million shares at an expected
While all eyes on fixated on global stock markets as the measure of “prosperity” and “growth” (or is it hubris?), the larger force at work beneath the dovish cooing of central bankers is foreign exchange: the relative value of nations’ currencies,
USDJPY: The pair extended its weakness on Monday leaving lower towards its key support located at the 111.66 level. On the downside, support comes in at the 111.00 level where a break if seen will aim at the 110.50 level.
The session on Tuesday features of the ISM Non-manufacturing PMI numbers coming out of America, and the Australian central bank releasing its monetary policy statement an interest-rate decision. With this being said, it is not likely to be a major
Shares of Groupon (GRPN) rallied in morning trading after the company announced a $250M investment from Atairos, the company founded by former Comcast (CMCSA, CMCSK) vice chairman and chief financial officer Michael Angelakis. As a result of the investment, Groupon
Healthcare Sector Leads the Market Lagging healthcare and biotech stocks found buyers today. The healthcare SPDR ETF (XLV) was up 1.05% to $69.38 as investors were probably seeking dividends and safety with fears about pricing tempered. The XLV is still
Albert discusses his recent interview with James Rickards and takes apart an Financial Times article critical of gold investors. Video Length: 00:18:25
Back in November and December of 2014, we released a 7 part series highlighting the weight of evidence piling up against U.S. stocks. In summary, our research showed a market top was upon us. If you weren’t with us back
American voters are expressing a lack of confidence in free trade and question whether the purpose of a corporation is to maximize shareholder wealth. These two ideas have guided U.S. economic policies for decades. Why are they tarnished in the
